Introduction
Hepatitis C virus (HCV) infects around 2.8% of the world's population, with estimates of 3 to 4 million new infections per year around the world [1, 2] . Chronic hepatitis C (CHC) develops in 10% to 20% of cases leading to liver cirrhosis, and 1% to 3% of those infected can develop hepatocellular carcinoma [3] [4] [5] .
The concept of quality of life (QOL) represents the patient's perception of the effect of the disease and the treatment given, upon physical, psychological and social aspects of their life [6] .
Patient-reported outcomes (PROs) are measures exclusively reported by the patients themselves, without the influence of the interviewer, on issues that include health-related quality of life (HRQOL) and work productivity (WP) [7] .
Patients infected with HCV present with a compromised HRQOL [8] [9] [10] and WP, with deteriorating rates of both absenteeism and presenteeism [11] . Treatment with interferon (IFN) is available to these patients but has been associated with limited therapeutic success rates and a high presence of side effects, including depression and fatigue [12, 13] .
The era of new direct-acting antivirals (DAAs) has promoted positive changes in CHC care. IFN-free DAAs are highly effective at viral eradication, whilst also improving patient well-being during and post-treatment, as observed using HRQOL and WP questionnaires [14, 15] .
To the best of our knowledge, no study evaluating PROs in HCV-infected patients treated with daclatasvir (DCV) in combination with sofosbuvir (SOF), with or without ribavirin (RBV), has been conducted. The aim of our study was therefore, to use PROs to compare the impacts of 3 different treatment regimens of: SOF and simeprevir (SMV); SOF and DCV and RBV; or SOF and DCV; on HRQOL and WP, before, during, and postdifferent treatment in a CHC patient sample.
Materials and Methods
From December 2015 to June 2016, the CHC cohort receiving IFN-free DAAs was evaluated under the following regimens:
SOF 400 mg and SMV 150 mg/day; SOF 400 mg and DCV 60 mg/day; or SOF 400 mg and DCV 60 mg and RBV 1000 to 1200 mg/ day; from 12 to 24 weeks, at the Liver Disease Outpatient Clinic of the Gastroenterology Department of the Gaffrée and Guinle University Hospital (HUGG), in Rio de Janeiro, Brazil. For the PRO evaluations, 4 widely used, self-administered questionnaires that were validated for CHC patients were applied [16] , either before or after their clinical consultations.
In patients undergoing a 12-week treatment regimen, the evaluation was performed before the beginning of the 
Results

Demographics and patient characteristics
Analysis was performed on 55 patients included in the study.
The socio-demographic characteristics of the sample indicated that 30 patients were older than 60 (range 42-84 years), most of them female (n = 38), and that 32 patients were defined as white and 35 lived with a partner. The time to disease diagnosis was more than 10 years in 24 patients, with genotype 1 being the most frequent (n = 49) followed by genotype type 2 (n = 6). 
Comparison of pre-treatment SF36, CLDQ, WPAI and FACIT-F scores
Descriptive statistics of the pre-treatment scores revealed that the type of treatment to which the patients were subjected to did not significantly influence the initial means of the scale components, indicating a probable uniformity between the groups in the pre-treatment stage (Table 3) .
Comparison of SF36, CLDQ, WPAI and FACIT-F scores from pre-treatment through to 4 weeks post end of treatment
In a global view of the scales, trends for positive variation in all 4 questionnaires were observed at Week 4 ( 16 patients who reported working, frequencies of 3, 9 and 4 patients, respectively. CLDQ = chronic liver disease questionnaire; DCV = daclatasvir; EWB = emotional well being; FACIT-F = functional assessment of chronic illness therapy; FS = fatigue ; FWB = functional well being; PWB = physical well being; RBV = ribavirin; SF36 = Medical Outcomes Study 36 -Item Short-Form Health Survey; SMV = simeprivir; SOF = sofosbuvir; SWB = social well being; WPAI = work productivity and activity impairment. the end of treatment (Table 5 ) and, mainly, at 4 weeks posttreatment (Table 6) .
No statistically significant difference in scale behavior according to treatment regimen, was observed by the KruskallWalls test.
More frequent decreases were observed at Week 4 of the treatment (Table 4) 16 patients who reported working, frequencies of 3, 9 and 4 patients, respectively. CLDQ = chronic liver disease questionnaire; DCV = daclatasvir; EWB = emotional well being; FACIT-F = functional assessment of chronic illness therapy; FS = fatigue ; FWB = functional well being; PWB = physical well being; RBV = ribavirin; SF36 = Medical Outcomes Study 36 -Item Short-Form Health Survey; SMV = simeprivir; SOF = sofosbuvir; SWB = social well being; WPAI = work productivity and activity impairment. 16 patients who reported working, frequencies of 3, 9 and 4 patients, respectively. CLDQ = chronic liver disease questionnaire; DCV = daclatasvir; EWB = emotional well being; FACIT-F = functional assessment of chronic illness therapy; FS = fatigue ; FWB = functional well being; PWB = physical well being; RBV = ribavirin; SF36 = Medical Outcomes Study 36 -Item Short-Form Health Survey; SMV = simeprivir; SOF = sofosbuvir; SWB = social well being; WPAI = work productivity and activity impairment. Table 5 . Descriptive statistics of scores variation (D) from pre-treatment to end of treatment of the SF36, CLDQ, WPAI e FACIT-F in 55 hepatitis C patients, by treatment regimens.
as instability in the maintenance of work activities over the course of the treatment, resulting in statistically nonsignificant results (Table 4 , 5 and 6).
At Week 4 post-treatment ( 
Discussion
This current study was the first to comparatively evaluate the effect of different treatment regimens applying SOF + DCV, Table 6 . 16 patients who reported working, frequencies of 3, 9 and 4 patients, respectively. CLDQ = chronic liver disease questionnaire; DCV = daclatasvir; EWB = emotional well being; FACIT-F = functional assessment of chronic illness therapy; FS = ; FWB = functional well being; PWB = physical well being PWB = physical well being; RBV = ribavirin; SF36 = Medical Outcomes Study 36 -Item Short-Form Health Survey; SMV = simeprivir; SOF = sofosbuvir; SWB = social well being; WPAI = work productivity and activity impairment.
SOF+ DCV + RBV, and SOF + SMV, upon PRO in patients with CHC.
The high number of patients treated with SOF + DCV, or SOF + DCV + RBV was due to the greater accessibility from the Ministry of Health for this therapy. In this scenario, no controlled randomization was applied, since patients were awaiting treatment. . The random allocation of the participants did not influence the data, leading to heterogeneity of the initial means, indicating that the pre-treatment groups can be compared ( Table 3 ).
The study was not blinded when the SVR result was applied.
The patients were not informed of the results of the viral eradication response to treatment in case this influenced the assessment scores of their well-being, as reported in previous studies. [15] .
In general, the IFN-free DAAs promoted improvements in
PROs scores (SF-36, CLDQ and FACIT-F). This result is in line with earlier studies demonstrating the benefit of other DAAbased treatment regimens on PROs [15, 27] .
The perception of a discrete decrease in the means at Week 4, predominantly in the DCV and RBV group, is in agreement with a study performed by Younossi et al. [28] . Younossi et al.
observed decreases in PROs of -7.0% in the group undergoing SOF and RBV treatment, as opposed to an increase of +11.6%
in the group undergoing ledipasvir and SOF treatment (p < 0.0001), which, in a multivariate analysis, represented an independent association with a -9.0% decrease in PROs in the SOF and RBV group [28] . The decrease in the means of the RBV group of our study may be justified by the possible unwanted side effects of this drug, such as anemia. However, the negative effect for RBV was not statistically significant.
The only previous study on the influence of DCV on PROs was a retrospective analysis of 33 patients co-infected with HIV. HIV co-infection may adversely affect the interpretation of the HRQOL deterioration [29] . In this study, SOF + DCV, or DCV and ledipasvir regimens were better tolerated and presented improved scores for SF-36 physical health (41.4 ± 9.7) and fatigue (37.8 ± 14.0) compared to the IFN-based regimen. Our study observed a consistent trend towards an improvement in patients treated with SOF + SMV, compared to the SOF + DCV and SOF + DCV + RBV groups.
The absolute difference of the means with regard to the pretreatment visit is more significant at Week 4 after the end of treatment, especially in the SOF + SMV groups. Despite the observed absolute differences of the means, the magnitudes of these differences were not statistically significant. It is possible that extending the evaluation to 12 weeks post-treatment could allow more time for a more significant positive effect on PROs to be observed.
The WPAI scores showed little responsiveness in detecting WP in our sample. We understand that the number of patients actually working and the informality at work that causes oscillation in these data is a reflection of the current socioeconomic situation in Brazil. Other researchers have found similar obstacles [30] .
Although the size of our patient population helped in understanding the impact of the new treatments on the HRQOL in HCV infected patients, a greater number of patients is required for multivariate analyses. 
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